WuXi Biologics Reports Solid 2024 Annual Results and Expects Accelerated Growth in 2025
Revenue grew 9.6% YoY to RMB 18,675.4 million, with non-COVID revenue up 13.1% YoY Adjusted EBITDA grew 14.4% YoY to RMB7,999.3 million and Adjusted Net Profit increased 9.0% YoY to RMB5,396.9 million Added 151 new integrated projects, including 13...
WuXi Biologics Named to CDP Water Security "A List" for Second Consecutive Year
Launching the Water Excellence Stewardship (WES) program to advance UN Sustainable Development Goal 6 (SDG6) Contributing to the 2025 World Water Day campaign to ensure the availability of water and sanitation for all SHANGHAI, March 21, 2025...
WuXi Biologics Included in S&P Global Sustainability Yearbook 2025
Ranking in top 1% of S&P Global CSA Score Inclusion in Global Yearbook for third consecutive year Leader in Green CRDMO to drive innovation for a healthier future SHANGHAI, March 11, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a...
WuXi Biologics Launches EffiX™ Microbial Expression Platform to Boost Recombinant Protein and Plasmid DNA Production
- EffiX™ is designed to meet the industry's demand for a high-yield, stable, and non-lysogenic E. coli expression system. It serves as a comprehensive solution for the development and manufacturing of non-monoclonal antibody (non-mAb) recombinant...
WuXi Biologics Again Passed GMP Inspection by Japan PMDA
WUXI, China, Feb. 27, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it has again passed the GMP inspection by Japan's...
WuXi Biologics Awarded Platinum Medal by EcoVadis Sustainability Rating for Second Consecutive Year
Ranked among the top 1% of more than 150,000 companies across 185 countries Trusted by global partners for strong sustainability commitment Recognized as a leader in Green CRDMO, driving innovation for a healthier future SHANGHAI, Feb. 18, 2025...
WuXi Biologics Recognized as Industry and Regional ESG Top-Rated Company by Morningstar Sustainalytics for Fifth Consecutive Year
Ranked among the top 1% of companies assessed in the pharmaceutical industry Recognized as a leader in Green CRDMO, driving innovation for a healthier future Committed to creating long-term value for all stakeholders SHANGHAI, Feb. 10, 2025...
WuXi Biologics Announces Agreement with Candid Therapeutics on Trispecific T-cell Engager
SHANGHAI and SAN DIEGO, Jan. 7, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269. HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced an agreement with Candid Therapeutics, Inc....
WuXi Biologics Ranks Top in 2024 Dow Jones Sustainability Indices for Second Consecutive Year
Named for second consecutive year named to prestigious DJSI list Leading green biologics solutions for a healthier future SHANGHAI, Jan. 2, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development,...
WuXi Biologics Included in UNGC 20 Case Examples of Sustainable Development for 20 Years Collection
Leading Green CRDMO Driven by Innovation for a Healthier Future Offering End-to-end Green Biologics Solutions for the Entire Industry SHANGHAI, Dec. 12, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research,...